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PURPOSE. We investigated the cross-sectional associations between macular pigment optical
density (MPOD), plasma lutein (L), and zeaxanthin (Z) concentrations and cognitive function
in 184 older adults of the 3-City-Bordeaux cohort.
METHODS. MPOD was measured using the two-wavelength autofluorescence method with a
modified scanning laser ophthalmoscope. Plasma L and Z (LþZ) concentrations were
determined by high-performance liquid chromatography and were considered either crude or
expressed as a ratio of the concentration of plasma lipids (total cholesterol [TC] þ
triglycerides [TG]). Cognitive performances were assessed using the following four separate
neuropsychological tests: the Mini-Mental State Examination (MMSE), the Isaacs Set Test (IST),
the Benton Visual Retention Test (BVRT), and the sum of the three free recalls of the Free and
Cued Selective Reminding Test (FCSRT). These test results were summarized by a composite
global cognitive z-score.
RESULTS. Higher MPOD at 0.58 was significantly associated with a higher composite z-score (b
¼ 0.15, 95% confidence interval [CI] 0.04–0.26), higher BVRT (b ¼ 0.39, 95%CI 0.08–0.70),
and higher IST (b ¼ 1.16, 95%CI 0.11–2.22) performances. Higher plasma LþZ concentrations
were significantly associated with higher IST scores (b ¼ 0.97, 95%CI 0.01–1.94).
Furthermore, a higher LþZ/TCþTG ratio was associated with a higher composite z-score
(b ¼ 0.12, 95%CI 0.01–0.23), along with higher IST (b ¼ 1.02, 95%CI 0.002–2.04) and FCSRT
(b ¼ 1.55, 95%CI 0.41–2.69) performances.
CONCLUSIONS. This analysis suggested that both higher MPOD and LþZ concentrations were
significantly associated with higher cognitive performances. However, MPOD measurements
have the advantage of being a fast and representative measure of long-term carotenoid intake.
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Located in the back of the eye (macula), the macular pigment(MP) is a yellow pigmented area composed of lutein (L) and
its isomers zeaxanthin (Z) and meso-zeaxanthin.1 The only
carotenoids selected by the macula are L and Z (LþZ).2
Additionally, LþZ are also detected in at least four brain areas
(cerebellum, frontal cortices, occipital cortices, and pons).3,4
Hence, interest in LþZ has expanded beyond the retina to
determine their possible contributions to brain function.5
It has been observed that LþZ concentrations in the brains
of centenarians were positively correlated with better cognitive
function, as assessed by the Mini-Mental State Examination
(MMSE); the Fuld Object Memory Evaluation; the Wechsler
Adult Intelligence Scale III (WAIS-III) Similarities; the Consor-
tium to Establish a Registry for Alzheimer’s Disease (CERAD)
verbal fluency, naming, and constructional praxis subtests; and
the Geriatric Deterioration Rating Scale (antemortem cognitive
measures).6 Additionally, several lines of evidence suggest a
positive relationship between both LþZ circulating concentra-
tions and intake, and cognitive functions.7–10
Furthermore, recent research has identified that better
cognitive performances were also significantly associated with
higher macular pigment optical density (MPOD).11,12
This accruing body of evidence suggests that LþZ concen-
trations in the plasma and MPOD could both be associated with
cognitive function. However, unlike LþZ plasma concentra-
tions, which mirror only recent dietary intake, MPOD could be
considered as a stable and representative measure of long-term
LþZ intake.13,14 Moreover, Vishwanathan et al.15,16 showed that
LþZ concentrations in the brain were positively correlated with
macular LþZ concentrations (i.e., MPOD) in both nonhuman
primates and humans. This suggests that MPOD could act as a
surrogate to measure brain LþZ concentrations.11
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In this cross-sectional study, we investigated the associa-
tions of both plasma carotenoid (LþZ) concentrations and
MPOD with cognitive performances in older adults from the
general population.
METHODS
Study Design and Participants
The ALIENOR (Antioxydants, LIpids Essentiels, Nutrition et
maladies OculaiRes) study is a population-based prospective
study focused on the associations of nutritional factors
(particularly antioxidants, MP, and fatty acids) with age-related
eye diseases such as glaucoma, age-related macular degenera-
tion (AMD), dry eye syndrome, and cataract. The complete
methodology of the ALIENOR study has been detailed
previously.17
Participants of the ALIENOR study were recruited from an
ongoing population-based study (3-City Study, 3C) on the
vascular risk factors for dementia.18 The 3C study included
9294 community-dwelling persons aged 65 years and older
from three French cities (Bordeaux, Dijon, and Montpellier),
among whom 2104 were recruited in Bordeaux. Subjects were
initially recruited in 1999 to 2001 and were followed up
approximately every 2 years after baseline.
The ALIENOR study consisted of an eye examination, which
was proposed to all participants after the third follow-up
(2006–2008) of the 3C cohort in Bordeaux (Figure). Partici-
pants in this study received follow-up communication approx-
imately every 2 years following the examination. Of the 1450
individuals reexamined between 2006 and 2008, 963 partici-
pants (aged 73 years or higher) were enrolled in the ALIENOR
study baseline eye examination. From these participants, 395
were reexamined between May 2008 and June 2009 in the
framework of an ancillary study on MP. A complementary eye
examination was proposed to all subjects diagnosed with early
AMD during the baseline examination and an equal number of
subjects without early AMD. This clinical exam included
measurement of the MPOD.
This research followed the tenets of the Declaration of
Helsinki. Participants gave written consent. The design of the
ALIENOR study was approved by the Ethical Committee of
Bordeaux (Comite´ de Protection des Personnes Sud-Ouest et
Outre-Mer III) in May 2006. The protocol for the 3C study was
approved by the Consultative Committee for the Protection of
Persons participating in Biomedical Research at Kremlin-
Bicetre University Hospital.
Among the 395 included participants, 4 participants
developed late AMD in the eye with the best visual acuity or
in both eyes and therefore were excluded from the present
analyses. One additional participant was also discarded as the
information about his intermediate AMD status was missing.
We also excluded 152 participants who had missing informa-
tion for MPOD or plasma LþZ concentrations. We next
excluded 23 participants who had incomplete data for
cognitive tests and 31 others who had missing information
on potential confounders to obtain a final sample size of n ¼
184 subjects.
Macular Pigment Measurement
The eye examination was performed at the Department of
Ophthalmology, University Hospital of Bordeaux. All subjects
underwent complete ocular examination. The examination
included a measurement of best-corrected visual acuity and
MPOD in both eyes as previously described.17 MPOD
measurements were collected using the modified confocal
scanning laser ophthalmoscope (mpHRA; Heidelberg Engi-
neering, Heidelberg, Germany).19 Autofluorescence images
FIGURE. The timelines of 3C, ALIENOR, and ALIENOR ancillary studies.
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were obtained at two wavelengths, based on the pioneering
work of Delori et al.20,21 Participants were positioned in front
of the tabletop and instructed to look straight ahead and to
remain steady; 208 autofluorescence images were then
obtained at excitation wavelengths of 488 and 514 nm of the
posterior pole, with a high-pass filter transmitting at a
wavelength greater than 530 nm. The MPOD was quantified
by calculating an MPOD map and comparing foveal and
parafoveal autofluorescence at 488 and 514 nm. Density maps
were processed to estimate the MPOD within a circle centered
on the fovea at different degrees of eccentricities (0.58, 18, 28,
and 68), using the software provided by the device manufac-
turer. Higher MPOD measurements were due to higher
concentrations of LþZ in the macula. The correlation of MPOD
values between each eye was greater than 0.8 for all degrees of
eccentricities measured. For each participant, the obtained
MPOD, expressed in optical density units, was the MPOD
measurement in the eye with the best visual acuity according
to the Parinaud scale. In this study, the MP at 0.58 and 18 are
reported.
Plasma Lutein and Zeaxanthin Determination
Fasting blood samples were obtained at the 10-year follow-up
(2009–2010) to the 3C study. Blood was collected in
heparinized vacutainers, centrifuged at 1000g for 15 minutes,
and stored (808C) until plasma carotenoid determination.
Extraction and HPLC analysis of plasma carotenoids were
performed as previously described22,23 with some modifica-
tions. Briefly, plasma (40 lL) was extracted with an ethanol/n-
butanol mixture containing b-apo-80-carotenal-methyloxime as
an internal standard. After centrifugation, the clear supernatant
was analyzed using a Shimadzu Prominence HPLC (LC-20A;
Kyoto, Kansai, Japan) equipped with an UV-Vis detector (set at
450 nm); the carotenoids a- and b-carotene, lycopene, b-
cryptoxanthin, and lutein and zeaxanthin were separated using
a ReproSil 80 ODS-2 column (3 lm, 2503 4.6 mm; Dr. Maisch
GmbH, Ammerbuch, Germany) and an eluent as described
previously24 at a flow rate of 1.5 mL/min. LþZ were not
baseline separated and are therefore reported as the sum of
LþZ. The present analyses were restricted to those circulating
carotenoids identified in the MP (i.e., LþZ concentrations
measured in lM).
Assessment of Cognitive Function
At the time of the MPOD assessment, four cognitive tests were
administered by trained psychologists to assess cognitive
functions as follows25: the MMSE,26 the Isaacs Set Test
(IST15),27 the Benton Visual Retention Test (BVRT),28 and
the Free and Cued Selective Reminding Test (FCSRT).29
1. The MMSE is a sum-score evaluating various dimensions
of cognition. It provides a brief and objective measure of
global cognitive functioning. The score ranges from 0 to
30 with higher values denoting better cognitive func-
tioning.
2. The IST15 is a test that evaluates verbal fluency abilities
and speed of verbal production. Subjects must give a list
of words that belong to a specific semantic category
(cities, color, animals, and fruits). The IST score was
obtained after 15 seconds, ranging from 0 to 40, with
higher values denoting better verbal fluency abilities.
3. The BVRT measures visual memory and visual percep-
tion. A stimulus card that displayed a geometric figure
was presented to the subjects for 10 seconds. Subjects
were then asked to choose the initial figure among four
possibilities. Fifteen figures were presented one at a
time, so the total score ranged from 0 to 15, with higher
values denoting better visual function.
4. The FCSRT evaluates memory performance and verbal
learning. In this analysis, we used the sum of three free
recalls, as this subscore is more sensitive to cognitive
function than total recall.30 The total score ranged from 0
to 48, with higher values denoting better cognitive
function.
These tests were chosen as they have been shown to be
clinically relevant (i.e., performances on these tests were
demonstrated to have been involved in the successive
emergence of cognitive deficits in the prodromal phase of
Alzheimer’s disease).31
To combine the results of all four individual cognitive tests,
a global composite measure was developed. The four
individual cognitive tests were standardized and averaged to
derive a cognitive z-score, which was considered the primary
outcome in the present analysis.
Other Variables
The interview conducted at the 10-year follow-up (2009–2010)
of the 3C study (Figure) included (1) demographic character-
istics such as sex, age, and educational level (no education or
primary school only, secondary school or higher), and (2)
clinical characteristics such as body mass index (BMI in kg/m2),
smoking (pack-year), Center for Epidemiological Studies-
Depression (CES-D) scale, hypertension, alcohol consumption
(number of glasses per week), and diabetes. The season was
defined according to the date of the blood drawing.
Apolipoprotein E e4 (ApoE4) alleles and intermediate AMD
status were also considered in the present analyses. For
participants who had not undergone cataract surgery, nuclear
cataract was defined as nuclear opalescence (NO) >3 and/or
nuclear color (NC) >3 on the LOCSIII classification.32 Baseline
cases of all-cause dementia were also reported (Table 1). Of
note, the diagnosis of dementia was based on a two-step
procedure.18
Moreover, total cholesterol (TC) and triglyceride (TG)
concentrations were measured by routine enzymatic methods
(mM). Measurement of TC and TG allows the ability to
determine the effect of concurrent levels of lipids on the
bioavailability of LþZ33 by calculating the LþZ/(TCþTG) ratio.
Statistical Analyses
Multiple linear regression models were used to examine the
relationship between MPOD, crude LþZ or LþZ/(TCþTG), and
cognitive scores.
Each cognitive test and the z-score (primary outcome) were
considered as separate outcomes in the multivariate linear
models. The variation in the cognitive tests (b and 95%
confidence interval [CI]) for 1-SD increase in plasma crude LþZ
or LþZ/(TCþTG), or MPOD was reported.
The MMSE score suffers from poor metrological properties,
mainly floor/ceiling effects and curvilinearity (i.e., varying
sensitivity to change), and a normalizing transformation of the
crude score was performed to ensure the normality assump-
tion, as previously suggested.34,35 Results are presented as
‘‘MMSE’’ in Tables 1, 3, 4, and 5 for clarity reasons, and higher
scores corresponded to higher global cognitive performances.
All other cognitive scores were standardized to compare the
obtained results.
In the multivariate analysis, we first adjusted for age, sex,
educational level, cataract surgery, nuclear cataract, and
intermediate AMD (model 1). Then adjustments for additional
clinical factors (smoking, BMI, ApoE4, CES-D, hypertension,
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alcohol consumption, and diabetes) were performed (model
2).
To study the association between cognitive tests and crude
LþZ or the ratio of LþZ/(TCþTG), multivariate analyses were
also adjusted for the season of the blood draw.
Multivariate analyses investigating the relationship between
cognitive tests and MPOD were adjusted for cataract surgery
and nuclear cataract but not for the season of the blood draw.
Indeed, recent studies have observed significant relationships
between cataract surgery, nuclear cataract, and MPOD
concentrations.36,37 Statistical analyses were conducted using
SAS Statistical package release 9.3 (SAS Institute, Inc., Cary, NC,
USA).
RESULTS
The study sample consisted of 184 persons aged 82.3 years on
average (SD 4.3 years) (Table 1). In our study, 68.5% of the
participants were women, and 71.8% had secondary or higher
educational level. Among all participants, 7.1% were de-
pressed, 10.9% were diabetic, 14.1% were carriers of the
ApoE4 allele, and 84.2% had hypertension. The mean (SD)
cognitive scores were 27.7 (1.9) for MMSE, 25.4 (7.5) for
FCSRT, 27.9 (6.2) for IST15, and 11.5 (1.9) for BVRT.
To summarize the ophthalmic characteristics: 56.0% of
participants had previous cataract surgery and 21.7% suffered
from nuclear cataract. The mean (SD) values of MPOD
measured at 0.58 and 18 were 0.7 (0.2) and 0.6 (0.2),
respectively. The mean (SD) values of crude LþZ concentra-
tions and of the ratio LþZ/(TCþTG) were 0.4 (0.3) lM and 0.06
(0.04) lmol/mmol, respectively. Additionally, the differences in
cognitive functions related to MPOD versus serum LþZ/TCþTG
might relate to the different characteristics of individuals who
have high (above median) versus low (below median) levels in
MPOD and serum as shown in Table 2.
In Table 3, higher MPOD values at 0.58 were significantly
associated with higher global cognitive performance; 1-SD
increase in MPOD at 0.58 was associated with a higher z-score
(b¼ 0.12, 95%CI 0.01–0.23) in the model adjusted for age, sex,
cataract surgery, nuclear cataract, educational level, and
intermediate AMD. However, there was no significant associ-
ation between MPOD at 0.58 and each of the cognitive tests
considered separately. After additional adjustments for smok-
ing, BMI, ApoE4, CES-D, hypertension, alcohol consumption,
and diabetes (model 2), higher MPOD values at 0.58 were
significantly associated with a higher composite global z-score
(b ¼ 0.15, 95%CI 0.04–0.26). Moreover, associations between
MPOD at 0.58 and IST (b¼1.16, 95%CI 0.11–2.22) and BVRT (b
¼ 0.39, 95%CI 0.08–0.70) performances became statistically
significant.
Similar results were obtained for MPOD at 18; in the partly
adjusted model 1 and in the fully adjusted model 2, higher
MPOD values at 18 were significantly associated with a higher
z-score (b¼ 0.11 95%CI 0.01–0.22 and b ¼ 0.14, 95%CI 0.03–
0.25, respectively). Moreover, higher MPOD values at 18 were
significantly associated with higher IST and BVRT scores in the
fully adjusted models.
The association between plasma LþZ concentrations and
cognitive performances was firstly controlled for age, sex,
educational level, season of the blood draw, cataract surgery,
nuclear cataract, and intermediate AMD (Table 4, model 1).
Higher plasma LþZ concentrations were significantly associat-
TABLE 1. Sociodemographic, Lifestyle, Plasma, and Macular Pigment Optical Density Characteristics (N¼ 184)
Characteristics Mean (SD) n (%) Median (Range)
Demographic characteristics
Sex
Women 126 (68.5)
Men 58 (31.5)
Age, y 82.3 (4.3) 81.7 (75.6–93.4)
Educational level
No education or primary school only 52 (28.3)
Secondary school or higher 132 (71.8)
Clinical characteristics
BMI, kg/m2
<23 40 (21.7)
23–27 81 (44.0)
>27 63 (34.2)
CES-D score 13 (7.1)
Hypertension 155 (84.2)
Diabetes 20 (10.9)
ApoE4 26 (14.1)
Smoking, pack-year 8.5 (18.3) 0 (0–102)
Alcohol, glasses/wk 6.1 (7.3) 7 (0–43)
All-cause dementia 7 (3.8)
MMSE 27.7 (1.9) 28 (20–30)
FCSRT 25.4 (7.5) 26 (0–40)
IST15 27.9 (6.2) 27.5 (14–43)
BVRT 11.5 (1.9) 12 (6–15)
Lutein þ zeaxanthin, lM 0.4 (0.3) 0.4 (0.03–2)
Lutein þ zeaxanthin/(TGþTC) ratio, lmol/mmol 0.06 (0.04) 0.06 (0.01–0.26)
MPOD 18, optical density unit 0.6 (0.2) 0.6 (0.1–1.2)
MPOD 0.58, optical density unit 0.7 (0.2) 0.7 (0.2–1.2)
Cataract surgery 103 (56.0)
Nuclear cataract 40 (21.7)
Intermediate AMD 89 (48.4)
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ed with higher IST scores but not with the composite z-score
or the MMSE, BVRT, or FCSRT performances.
In the fully adjusted models, the association between
plasma LþZ concentrations and IST scores remained statisti-
cally significant. Higher concentrations of plasma LþZ were
only associated with higher IST performances.
Additionally, higher LþZ/TGþTC ratios were significantly
associated with a higher composite z-score and with higher
FCSRT performances (Table 5, model 1). After full adjustment,
these associations remained significant; furthermore, higher
LþZ/TGþTC ratios were significantly associated with higher IST
performances.
DISCUSSION
Among 3C participants, our previous work has shown that
higher values of plasma crude L concentrations and the L/
(TGþTC) ratio were both significantly associated with a
decreased risk of incident dementia.38 In the present analysis,
higher MPOD was significantly associated with higher cogni-
tive function (considered as a composite z-score) and
specifically, with higher verbal fluency abilities and visual
memory. This relation was independent of major confounders
including cataract surgery, nuclear cataract, and intermediate
AMD status. Regarding circulating MPs, a positive association
was observed only between crude concentrations of LþZ and
verbal fluency abilities, while a higher plasma LþZ/TGþTC
ratio was significantly associated with a higher global cognitive
z-score, episodic memory, and verbal fluency.
To our knowledge, this study is the first to consider both
MPOD and circulating LþZ concentrations (as a function of
plasma lipids). The significant associations between MPOD and
cognitive performances reported in this study are consistent
with previous reports of relationships of MPOD (measured by a
TABLE 2. Description of the Relationship of Covariates to MPOD, LþZ, and LþZ/TCþTG Ratios
Covariates
MPOD 0.58* MPOD 18* Lutein þ Zeaxanthin*
Lutein þ Zeaxanthin/
(TGþTC) Ratio*
Below
Median,
N ¼ 95
Above
Median,
N ¼ 89
Below
Median,
N ¼ 96
Above
Median,
N ¼ 88
Below
Median,
N ¼ 92
Above
Median,
N ¼ 92
Below
Median,
N ¼ 91
Above
Median,
N ¼ 93
Demographic characteristics
Sex, %
Men 35.8 27.0 37.5 25.0 37.0 26.1 30.8 32.3
Women 64.2 73.0 62.5 75.0 63.0 73.9 69.2 67.7
Age, y, mean (SD) 81.9 (4.0) 82.8 (4.5) 82.0 (4.1) 82.7 (4.4) 82.1 (4.2) 82.6 (4.3) 82.2 (4.3) 82.4 (4.2)
Educational level, %
No education or primary school only 24.2 32.6 25.0 31.8 29.4 27.2 31.9 24.7
Secondary school or higher 75.8 67.4 75.0 68.2 70.7 72.8 68.1 75.3
Clinical characteristics
BMI, kg/m2
<23 18.9 24.7 18.8 25.0 17.4 26.1 15.4 28.0
23–27 38.9 49.4 39.6 48.9 41.3 46.7 46.2 41.9
>27 42.1 25.8 41.7 26.1 41.3 27.2 38.5 30.1
CES-D score, % 7.4 6.7 7.3 6.8 7.6 6.5 6.6 7.5
Hypertension, % 82.1 86.5 82.3 86.4 90.2 78.3 90.1 78.5
Diabetes, % 13.7 7.9 14.6 6.8 14.1 7.6 12.1 9.7
ApoE4, % 12.6 15.7 11.5 17.0 14.1 14.1 14.3 14.0
Smoking, pack-year, mean (SD) 8.4 (17.0) 8.5 (19.6) 8.8 (17.0) 8.1 (19.6) 10.1 (20.8) 6.9 (15.3) 7.8 (17.0) 9.1 (19.5)
Alcohol, glasses/wk, mean (SD) 7.2 (8.6) 4.9 (5.5) 7.2 (8.6) 4.9 (5.4) 6.7 (7.5) 5.5 (7.1) 6.4 (7.7) 5.8 (7.0)
Cataract surgery, % 42.1 70.8 41.7 71.6 55.4 56.5 56.0 55.9
Nuclear cataract, % 40.0 2.2 39.6 2.3 22.8 20.7 23.1 20.4
Intermediate AMD, % 51.6 44.9 51.0 45.5 43.5 53.3 44.0 52.7
* MPOD, LþZ, and LþZ/TCþTG ratios are expressed in quantiles (below median versus above median).
TABLE 3. Multivariate Association Between Macular Pigment Optical Density, Considering Two Eccentricities and Cognitive Performances,
ALIENOR Study (N ¼ 184)
Cognitive
Performances
Model 1 Model 2
MPOD 0.58 MPOD 18 MPOD 0.58 MPOD 18
b (95%CI) P Value b (95%CI) P Value b (95%CI) P Value b (95%CI) P Value
z-score* 0.12 (0.01, 0.23) 0.03 0.11 (0.01, 0.22) 0.04 0.15 (0.04, 0.26) 0.01 0.14 (0.03, 0.25) 0.02
FCSRT 1.12 (0.05, 2.28) 0.06 1.10 (0.05, 2.25) 0.06 1.17 (0.03, 2.37) 0.06 1.12 (0.06, 2.30) 0.06
IST 0.93 (0.09, 1.94) 0.07 0.90 (0.10, 1.90) 0.08 1.16 (0.11, 2.22) 0.03 1.12 (0.08, 2.16) 0.03
MMSE 1.34 (0.95, 3.63) 0.25 1.26 (1.00, 3.52) 0.27 1.48 (0.93, 3.89) 0.23 1.32 (1.04, 3.69) 0.27
BVRT 0.29 (0.02, 0.59) 0.06 0.23 (0.07, 0.53) 0.13 0.39 (0.08, 0.70) 0.02 0.32 (0.02, 0.63) 0.04
* Composite global cognitive z-score calculated by averaging the z-scores of MMSE, IST, FCSRT, and BVRT. Model 1: adjusted for age, sex, cataract
surgery, nuclear cataract, educational level, and intermediate AMD. Model 2: model 1 þ additional adjustment for smoking, body mass index,
apolipoprotein E e4 alleles, Center for Epidemiological Studies-Depression score, hypertension, alcohol consumption, and diabetes.
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variety of techniques) to cognitive function. In a cross-sectional
study of 108 elderly participants, cognitive performances
showed significant associations with MPOD, whereas associa-
tions with serum LþZ concentrations were less consistent.12
Kelly et al.10 compared two groups of participants (subjects
free of retinal disease with low MPOD and subjects with early
AMD) in a cross-sectional study. Higher MPOD was significantly
associated with better cognition in both groups, while serum
LþZ concentrations were not associated with cognitive
performances. Additionally, in a large cross-sectional study of
older adults aged ‡50 years (n¼ 4453), lower values of MPOD
were significantly associated with poorer cognitive perfor-
mances.39 The present study is the first to adjust serum LþZ for
serum lipids, as previously suggested for the analysis of vitamin
E concentrations.40 Brady et al.41 observed that serum LþZ
concentrations were significantly and positively related to HDL
and non-HDL cholesterol. Indeed, carotenoids are not distrib-
uted uniformly between lipoproteins.42 Particularly, LþZ are
carried predominantly by HDL (53%) and in lower proportions
by LDL (31%) followed by VLDL (16%).43 These findings
suggest that the correlation of absolute plasma carotenoids to
concurrent plasma lipids cannot be neglected,33 and not
standardizing for lipids adds random misclassification, thus
biasing the estimates toward the null. Thus, one should
consider the LþZ/TCþTG ratio as a more accurate indicator of
the true LþZ plasma concentrations.
Altogether, the available literature to date, mainly cross-
sectional, underlines a consistent relationship between higher
MP constituents, as measured by circulating concentrations of
LþZ and MPOD, and higher cognitive performances via
assessment of several cognitive domains by different neuro-
psychological tests. Interestingly, as in the present work, it
appears that MPOD is likely more sensitive than circulating
concentrations of LþZ to cognitive performances. Indeed,
higher MPOD was usually associated with several cognitive
domains, while LþZ concentrations, somewhat more fluctuat-
ing and dependent on recent dietary intake, were only
associated with some particular cognitive tests (i.e., mainly
verbal fluency test). As LþZ circulating levels and MPOD are
mainly determined by dietary habits, our results would
encourage adoption of a healthier dietary lifestyle, such as
following a Mediterranean diet25,38 or a MIND diet,44,45 in
which green leafy vegetables (providers of L/Z) are highly
represented.
Furthermore, data from our group suggested that during the
prodromal phase of dementia, a decrease in IST and BVRT
scores occurs more than a decade before the diagnosis of
dementia.31 More specifically, the first measurable decline in
cognitive function was detected on the IST. In other words, the
IST might be more sensitive to cognitive decline than other
cognitive tests, as suggested by its significant association with
MPOD, plasma LþZ concentration, and the LþZ/TGþTC ratio.
Altogether, these arguments provide a comprehensive insight
into the nonsignificant (borderline) association between crude
LþZ plasma concentrations and the global cognitive test.
However, our results must be interpreted with caution, first
because of the cross-sectional design of our study, which
cannot exclude reverse causality. Second, taking into account
other dietary factors known to influence cognition such as
omega-3 fatty acids46 would have improved and strengthened
our results. Third, a selection bias cannot be dismissed;
participants not included (n ¼ 211) in the present analysis
were more depressed, were more diabetic, were more
demented, and had higher alcohol consumption than those
included (Supplementary Table S1). Moreover, the small
sample size may have decreased the statistical power of the
present study and could thus limit the generalizability of the
results.
However, this analysis was conducted on a subsample of a
population-based cohort of elderly people, which, as a whole,
was representative of elderly people aged >75 years living in
Bordeaux in 2009 and 2010.47 Furthermore, this study is the
first to relate the concurrent levels of lipids on the
bioavailability of LþZ to cognitive performances. Finally,
multiple potential confounders were considered, including
cataract status (presence of nuclear cataract, cataract surgery).
Indeed, cataract, and especially its nuclear subtype, may lead to
an underestimation of MPOD values. For instance, in a study by
Sasamoto et al.,37 in 40 subjects affected by nuclear cataract,
preoperative MPOD correlated negatively with preoperative
nuclear color score and MPOD increased from 0.35 DU
preoperatively to 0.60 DU postoperatively. It is noteworthy
that serum LþZ concentrations are inversely related to the risk
of cataract.48 Moreover, cataract surgery may be related to
better cognitive function,49 although this latter relationship is
not fully understood.50,51 Cataract status was thus carefully
taken into account in all our models.
TABLE 4. Multivariate Regression Analyses of the Association Between
Cognitive Test Performance and Plasma Lutein þ Zeaxanthin Concen-
trations (N¼ 184)
Cognitive
Test
Lutein þ Zeaxanthin
Model 1 Model 2
b (95%CI)
P
Value b (95%CI)
P
Value
z-score* 0.09 (0.01, 0.19) 0.07 0.09 (0.01, 0.19) 0.09
FCSRT 0.91 (0.15, 1.97) 0.09 0.98 (0.12, 2.07) 0.08
IST 0.97 (0.04, 1.89) 0.04 0.97 (0.01, 1.94) 0.047
MMSE 1.73 (0.35, 3.81) 0.10 1.38 (0.81, 3.56) 0.21
BVRT 0.03 (0.31, 0.25) 0.82 0.02 (0.30, 0.27) 0.91
* Composite global cognitive z-score calculated by averaging the z-
scores of MMSE, IST, FCSRT, and BVRT. Model 1: adjusted for age, sex,
season, cataract surgery, nuclear cataract, educational level, and
intermediate AMD. Model 2: model 1 þ additional adjustment for
pack-year of cigarettes, body mass index, apolipoprotein E e4 alleles,
Center for Epidemiological Studies-Depression score, hypertension,
alcohol consumption, and diabetes.
TABLE 5. Multivariate Regression Analyses of the Association Between
Cognitive Test Performance and Plasma Lutein þ Zeaxanthin/(Triglyc-
erides þ Total Cholesterol) Ratio (N¼ 184)
Cognitive
Test
Lutein þ Zeaxanthin/(TGþTC) Ratio
Model 1 Model 2
b (95%CI)
P
Value b (95%CI)
P
Value
z-score* 0.12 (0.01, 0.22) 0.03 0.12 (0.01, 0.23) 0.03
FCSRT 1.40 (0.29, 2.52) 0.01 1.55 (0.41, 2.69) 0.008
IST 0.97 (0.01, 1.95) 0.053 1.02 (0.002, 2.04) 0.049
MMSE 1.85 (0.35, 4.05) 0.10 1.49 (0.82, 3.80) 0.20
BVRT 0.007 (0.29, 0.30) 0.96 0.03 (0.27, 0.33) 0.86
* Composite global cognitive z-score calculated by averaging the z-
scores of the four tests. Model 1: adjusted for age, sex, season, cataract
surgery, nuclear cataract, educational level, and intermediate AMD.
Model 2: model 1 þ additional adjustment for pack-year of cigarettes,
body mass index, apolipoprotein E e4 alleles, Center for Epidemiolog-
ical Studies-Depression score, hypertension, alcohol consumption, and
diabetes.
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In conclusion, higher MPOD and plasma LþZ concentra-
tions (expressed as a function of plasma lipids) were both
significantly associated with higher cognitive performances
among French elderly community dwellers. The advantages of
using MPOD over plasma LþZ measurements to assess the
relationship between these MP components and cognitive
functions are clear. Notably, MPOD is a fast and stable indicator
of long-term carotenoid status since it is less impacted by short-
term dietary variations compared to plasma LþZ concentra-
tions. Additionally, MPOD can also be a noninvasive tool to
assess MP constituents (e.g., when measured via heterochro-
matic flicker photometry). Moreover, many authors claim that
the retina can be considered as a window to the brain, the eye
being an extension to the central nervous system.52,53
Future work will investigate the evolution of cognitive
performances through subsequent waves of the 3C study in
relation to baseline MPOD and plasma LþZ concentrations.
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